Janus Henderson Group Adds $40M in Apogee Therapeutics, Inc. ($APGE)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Janus Henderson Group increased its position in Apogee Therapeutics, Inc. ($APGE) by 14.45% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,360,596 shares of Apogee Therapeutics, Inc. after buying 297,992 shares during the quarter. Janus Henderson Group's holdings in Apogee Therapeutics, Inc. were worth $313.32 million as of its most recent filing.
Apogee Therapeutics, Inc. Stock Down 1.7%
Shares of Apogee Therapeutics, Inc. ($APGE) traded around $132.73 on Saturday, down 1.7% for the day.
Apogee Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Get Apogee Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $APGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.